Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.53 |
| ▸ | NOS1 | P29475 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | STAT1 | P42224 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetophenone SCHEMBL14860336 | 0.88 | PTGS2 (0.54) | NOS3NOS1MAPTRAB9ANPC1 | |
| Acetophenone SCHEMBL29127417 | 0.86 | PTGS2 (0.51) | NOS3NOS1MAPTRAB9ANPC1 | |
| SCHEMBL27794977 | 0.84 | TP53 (0.47) | NOS3NOS1MAPTRAB9ANPC1 | |
| SCHEMBL13882615 | 0.83 | TP53 (0.53) | MAPTSTAT3TP53SCN1ASCN2A | |
| SCHEMBL13449659 | 0.81 | TP53 (0.52) | NPC1SMN1; SMN2TP53SCN1ASCN2A | |
| SCHEMBL28083230 | 0.81 | TP53 (0.52) | NPC1SMN1; SMN2TP53SCN1ASCN2A | |
| Acetophenone SCHEMBL28408032 | 0.81 | PTGS2 (0.47) | NOS3NOS1MAPTSMN1; SMN2TP53 | |
| SCHEMBL27680505 | 0.80 | KMT2A (0.41) | NOS3NOS1MAPTRAB9ANPC1 | |
| SCHEMBL14020632 | 0.79 | TP53 (0.50) | STAT3TP53SCN1ASCN2ASCN3A | |
| SCHEMBL15042744 | 0.79 | NOS1 (0.52) | NOS1MAPTSTAT3TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025229046-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-11-06 | — | — | WO | disclosed |
| EP-4644375-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-11-05 | — | — | EP | disclosed |
| EP-3795563-B1 | INDOLINE ANALOGS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3795563-B1 | INDOLINE ANALOGS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-114671816-B | Preparation method of axial chiral aryl triazole compound | 浙江大学 | 2023-11-17 | — | — | CN | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| CN-109219594-B | Indoline analogue and application thereof | 英克特诺治疗公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114671816-A | Preparation method of axial chiral aryl triazole compound | 浙江大学 | 2022-06-28 | — | — | CN | disclosed |
| WO-2014095633-A1 | PROCESS FOR PRODUCING WATER-ABSORBING POLYMER PARTICLES | BASF SE (DE) | 2014-06-26 | — | — | WO | disclosed |
| CN-103665170-A | Peptide therapeutic conjugates and uses thereof | ANGIOCHEM INC | 2014-03-26 | — | — | CN | disclosed |
| CN-102348723-A | Peptide therapeutic agent conjugates and uses thereof | ANGIOCHEM INC | 2012-02-08 | — | — | CN | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20090269555-A1 | SURFACE NANOPATTERNING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269555-A1 | SURFACE NANOPATTERNING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-29 | — | — | US | disclosed |
| US-7524408-B2 | photoreduction of an azide, photodecarbozylation of a carboxylic acid, photodenitrogenation and Wolff rearrangement of a diazoketone, and the photoreduction of an aromatic nitrocompound; charged nanoparticle from CdS and CdSe compounds as path-directable nanoparticle; | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524408-B2 | photoreduction of an azide, photodecarbozylation of a carboxylic acid, photodenitrogenation and Wolff rearrangement of a diazoketone, and the photoreduction of an aromatic nitrocompound; charged nanoparticle from CdS and CdSe compounds as path-directable nanoparticle; | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-28 | — | — | US | disclosed |
| CN-100340556-C | Arylimidazole derivatives, preparation thereof and therapeutic use thereof | SOD CONSEILS RECH APPLIC (FR) | 2007-10-03 | — | — | CN | disclosed |
| CN-1671701-A | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | SOD CONSEILS RECH APPLIC (FR) | 2005-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | NOS3 3835/4885NOS1 4313/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.